Biotech company Biosergen has had such good results with the first four groups of subjects in their Phase 1 study that they are now launching

Nexcom’s half-year results offered little news to the market that had not already been communicated in connection with the company’s capital increase in Q2. The

Biosergen’s H1-2022 report and major shareholder loan to the company point to more share price triggers this year and ahead of product launch and thus

Lifecare has today published its half-year results. It supports the investment case for an early capital injection and a significant share price trigger as early

30 million Americans need a hearing aid. Many of these don’t have one because they can’t afford one, as subsidies are not generally provided in

If you want to invest in Novo Nordisk, you should look at Lifecare Most investors – especially Novo Nordisk shareholders – know that diabetes is

In Denmark alone, 270 people die each year from birthmark cancer, the most common cancer in the 15-34 age group, and 2,500 new cases are

Nexcom (share price DKK 2.76), listed on First North Denmark, has completed a capital increase and a strengthening of its capital structure to ensure continued